

Study of Relationship between Endotoxemia and Cardiovascular Disease in Hemodialysis Patients

Thesis

Submitted for Partial Fulfillment of Master Degree in Internal Medicine

By

UmniahAbou El-ElaAbdo

M.B,B.ch

Faculty of Medicine-Ain Shams University

Under supervision of

Prof. Dr.Mohamed Ali Ibrahim

Professor of Internal Medicine and Nephrology

Faculty of Medicine-Ain Shams University

Dr. MahaAbd El MoneimBehairy

Lecturer of Internal Medicine & Nephrology

Faculty of Medicine-Ain Shams University

Dr. Ahmad ElsayedYousef

Lecturer of Cardiology

Faculty of Medicine-Ain Shams University

Faculty of Medicine

Ain shams University

2015

دراسة العلاقة بين الاندوتكسيميا وأمراض القلب
والشرايينفى مرض الغسيل الكلوي

رسالة

توطئة للحصول على درجة الماجستير في أمراض الباطنة
العامة

مقدم من

أمنية أبو العلا عبده

بكالوريوس الطب والجراحة

كلية الطب - جامعة عين شمس

تحت إشراف

الأستاذ الدكتور / محمد علي إبراهيم

أستاذ الأمراض الباطنة والكلية

كلية الطب - جامعة عين شمس

الدكتورة / مها عبد المنعم بحيرى

مدرس امراض الباطنة والكلية

كلية الطب - جامعة عين شمس

الدكتور / أحمد السيد يوسف

مدرس أمراض القلب

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

2015



- ✍ All praise are to **Allah** and all thanks. He has guided and enabled me by his mercy to fulfill this thesis, which I hope to be beneficial for people.
- ✍ I would like to express my deepest gratitude and sincere appreciation to **Prof. Dr. Mohamed Ali Ibrahim**, Professor of Internal Medicine and Nephrology, Faculty of medicine, Ain Shams University for his encouragement, his kind support and appreciated suggestions that guided me to accomplish this work.
- ✍ I am also grateful to, **Dr. Maha Abd El Moneim Behairy**, Lecturer of Internal Medicine & Nephrology, Ain Shams University, who freely gave her time, effort and experience along with continuous guidance throughout this work.
- ✍ A lot of thanks are extended to **Dr. Ahmad Elsayed Yousef**, Lecturer of Cardiology, Faculty of Medicine, Ain Shams University for his effort, constant encouragement and advice whenever needed.

✍ **Umniah Abou El-Ela Abdo**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العليم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Contents

Subjects	Page
• List of Abbreviations.....	I
• List of Tables.....	V
• List of Figures.....	IX
• Introduction.....	1
• Aim of the Work.....	3
• Review of literature	
- Chapter (I): Cardiovascular diseases in hemodialysis patients.....	4
- Chapter(II):Endotoxemia in hemodialysis patients....	27
- Chapter (III): Management of endotoxemia in hemodialysis patients.....	48
• Patients and Methods.....	67
• Results.....	73
• Discussion.....	114
• Summary& Conclusion.....	125
• Recommendations.....	130
• References.....	131
• Arabic summary	

List of Abbreviations

Abb.	Meaning
ACS.....	Acute coronary syndrome
ADMA	Asymmetric dimethyl arginine
ADP.....	Adenosine diphosphate
AGEs.....	Advanced glycation end-products
ALP	Alkaline phosphatase
AMI.....	Acute myocardial infarction
ANSI	American National Standards Institute
BMI	Body mass index
BP.....	Blood pressure
BUN	Blood urea nitrogen
Ca	Calcium
CACS	Coronary artery calcium score
CAPD.....	Continuous ambulatory peritoneal dialysis
CaSR	Calcium sensing receptors
CCA	Common carotid artery
CHD	Coronary heart disease
CHF.....	Congestive heart failure
cIMT	Carotid artery intima _media thickness
CKD	Chronic kidney disease
CMRI	Cardiac magnetic resonance imaging
COP.....	Cardiac output
CPFA.....	Coupled plasma filtration adsorption
CRP	C-reactive protein
CRRT	Continuous renal replacement therapy
cTnI.....	Cardiac troponin I
cTnT.....	Cardiac troponin T
CV	Cardiovascular
CVA	Cerebrovascular accident

List of Abbreviations (Cont..)

Abb.	Meaning
CVDs.....	Cardiovascular diseases
DIC.....	Disseminated intravascular coagulation
E	Early trans-mitral diastolic velocity
e'	Early diastolic velocity of the mitral annulus
EAA	Endotoxin activity assay
EBPG	European Best Practice guidelines
EF	Ejection fraction
EPO	Erythropoietin
ESA	Erythropoiesis-stimulating agents
ESP.....	Endotoxin scattering photometry
ESRD	End stage renal disease
FAO.....	The Food and Agriculture Organization
FGF23	Fibroblast growth factor 23
GDF-15	Growth differentiation factor-15
GFR.....	Glomerular filtration rate
GIT	Gastrointestinal tract
GLP-2.....	Glucagon-like peptide 2
HCO	High cut-off
HD.....	Hemodialysis
HDF.....	Hemodiafiltration
HF	Heart failure
HGB	Hemoglobin
HsCRP.....	High sensitivity CRP
HsTnI	High-sensitivity troponin I
IDWG.....	Inter-dialytic weight gain
IVSd	Inter ventricular septum diameter in diastole
LA	Left atrium
LAD	Left atrial dimension

List of Abbreviations (Cont..)

Abb.	Meaning
LAL.....	Limulus amebocyte lysate
LAVi	Left atrial volume index
LBP	Lipopolysaccharide binding protein
LPS.....	Lipopolysaccharide
LV	Left ventricle
LVEDD	Left ventricle end-diastolic diameter
LVESD.....	Left ventricle end-systolic diameter
LVH	Left ventricular hypertrophy
LVM.....	Left ventricular mass
LVMi	Left ventricular mass index
LVMi	Left ventricular mass index
LVPW	Left ventricular posterior wall diameter in diastole
MAMPs.....	Microbe-associated molecular patterns
MAP	Mean arterial blood pressure
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
MD2	Myeloid differentiation factor 2
MI.....	Myocardial infarction
Na.....	Sodium
NAFLD	Non-alcoholic fatty liver disease
NFAT	Nuclear factor of activated T cells
NO.....	Nitric oxide
NOS.....	Nitric oxide synthase
NT-pro-BNP	N-terminal prohormone brain natriuretic peptide
P	Phosphate
PD	Peritoneal dialysis

PE: Pulmonary embolism

List of Abbreviations (Cont..)

Abb.	Meaning
PPAR γ	Peroxisomal proliferator activated receptor gamma
PRRs	Pattern-recognition receptors
PTH	Parathyroid hormone
PTX3	Pentraxin 3
RAGE.....	Receptors for advanced glycation end products
RO	Reverse osmosis
RWT.....	Relative wall thickness
SCD.....	Sudden cardiac death
TER	Trans-epithelial electrical resistance
TG	Triglycerides
TIA	Transient ischemic attacks
TLR4.....	Toll-like receptor 4
TSAT.....	Transferrin saturation
UF	Ultrafiltration
UFR.....	Ultrafiltration rate
URR	Urea reduction ratio
VSMC	Vascular smooth muscle cell
WHO	The World Health Organization
ZO-1	Zonula occludens 1
2D.....	Two dimensional
3D.....	Three dimensional

List of Tables

Table No	Title	Page
Table (1a)	Characteristics of the studied patients.	75
Table (1b)	Characteristics of the studied patients.	76
Table (2a)	Comparison between studied groups regarding echocardiographic parameters.	77
Table (2b)	Comparison between studied groups regarding echocardiographic parameters.	78
Table (3)	Comparison between studied groups regarding laboratory results.	79
Table (4a)	Comparison between studied groups regarding characteristics of the patients.	80
Table (4b)	Comparison between studied groups regarding characteristics of the patients.	81
Table (5a)	Correlation between pre-dialysis endotoxin level and echocardiographic parameters.	82
Table (5b)	Correlation between pre-dialysis endotoxin level and echocardiographic parameters.	83
Table (6)	Correlation between pre-dialysis endotoxin level and laboratory results.	84
Table (7a)	Correlation between pre-dialysis endotoxin level and characteristics of the patients.	85
Table (7b)	Correlation between pre-dialysis endotoxin level and characteristics of the patients.	86

List of Tables(Cont..)

Table No	Title	Page
Table (8a)	Correlation between post-dialysis endotoxin level and echocardiographic parameters.	87
Table (8b)	Correlation between post-dialysis endotoxin level and echocardiographic parameters.	89
Table (9)	Correlation between post-dialysis endotoxin level and laboratory results.	90
Table (10a)	Correlation between post-dialysis endotoxin level and characteristics of the patients.	91
Table (10b)	Correlation between post-dialysis endotoxin level and characteristics of the patients.	92
Table (11a)	Correlation between endotoxin delta change and echocardiographic parameters.	93
Table (11b)	Correlation between endotoxin delta change and echocardiographic parameters.	95
Table (12)	Correlation between endotoxin delta change and laboratory results.	96
Table (13a)	Correlation between endotoxin delta change and characteristics of the patients.	97
Table (13b)	Correlation between endotoxin delta change and characteristics of the patients	98
Table (14)	Correlation between LV mass index and laboratory results.	99

List of Tables_(Cont..)

Table No	Title	Page
Table (15)	Correlation between LV hypertrophy and laboratory results.	100
Table (16)	Correlation between LV mass index and patients' characteristics	101
Table (17)	Relation between LVH and patients' characteristics.	102
Table (18)	Description of the carotid duplex parameters.	103
Table (19)	Comparison between the studied groups regarding the carotid duplex parameters.	104
Table (20)	Relation between CCA atherosclerosis and laboratory results.	105
Table (21a)	Relation between CCA atherosclerotic changes and characteristics of the patients.	106
Table (21b)	Relation between CCA atherosclerotic changes and patient's characteristics.	107
Table (22)	Correlation between CCA intimal thickness and laboratory results.	108
Table (23a)	Correlation between CCA intimal thickness and patients' characteristics.	109
Table (23b)	Correlation between CCA intimal thickness and patients' characteristics.	110
Table (24)	Multivariate analysis for factors affecting endotoxin delta change (linear regression for determinants of endotoxin delta change).	111

List of Tables_(Cont..)

Table No	Title	Page
Table (25)	Multivariate analysis for factors affecting MVE/A ratio (linear regression for determinants of mv e/a ratio).	112
Table (26)	Univariate analysis for factors affecting MVE/A ratio (linear regression for determinants of MV E/A).	113

List of Figures

Figure No	Title	Page
Figure (1)	Causes of death in prevalent HD patients.	5
Figure (2)	Dose-effect relation between HsCRP level and IL-6:IL-10 ratio and the number of LV segments that subsequently developed wall motion abnormalities during or after HD.	7
Figure (3)	Comparison of the distribution of values of left atrial dimension (A - LAD) and left atrial volume index (B - LAVi) in subjects from Group I (control) and Group II (upper quartile of CRP) of the study population.	7
Figure (4)	Changes in blood volume, E and mean e' in comparison to predialysis values.	17
Figure (5)	Kaplan-Meier survival curves for CV mortality in patients with CACS above 800 Agatston units versus patients with lower CACS values.	20
Figure (6)	Frequent HD is associated with favorable changes in LV mass.	26
Figure (7)	Schematic diagram of endotoxin molecule structure.	28
Figure (8)	Bar graphs depicting the TER in intestinal epithelial cell monolayers incubated for 24h in regular media and those incubated in media containing 42 or 72 mg/dl urea.	31

List of Figures (Cont..)

Figure No	Title	Page
Figure (9)	Representative Western blots and group data depicting protein abundance of occludin, claudin-1 and ZO-1 in intestinal epithelial cell monolayers incubated for 24h in media containing 42 mg/dl urea alone and those incubated in media containing 42 mg/dl urea plus urease.	31
Figure (10)	Risk factors aggravating GI translocation of endotoxin in HD patients.	35
Figure (11)	Distribution of circulating endotoxin levels across the spectrum of CKD patients.	36
Figure (12)	The inflammatory pathway induced by endotoxin.	38
Figure (13)	Predialysis endotoxin levels were significantly correlated with a) the number of myocardial stunned segments and b) cTnT, a marker of myocardial damage.	42
Figure (14)	Effect of intraperitonealLPS injection on the cardiac muscle of the mice.	43
Figure (15)	Effect of intraperitonealLPS injection on IL-6 expression and collagen fraction area of the LV.	44
Figure (16)	Probiotics benefit the host by communicating with a variety of cell types.	54